title: Bleomycin sclerosis of pelvic lymphoceles.
abstract: OBJECTIVE
  To describe the results of postoperative pelvic lymphocele treatment by means of percutaneous drainage and sclerosis with bleomycin.
  
  
  METHODS
  Four patients underwent treatment of pelvic lymphoceles by percutaneous tube drainage followed by instillation of bleomycin under fluoroscopic guidance at a concentration of 1 unit/mL. Bleomycin instillation was repeated at weekly intervals until the tube output was less than 10 mL per day. Three of four patients underwent unsuccessful sclerosis previously with alcohol, doxycycline, or povidone iodine.
  
  
  RESULTS
  Lymphocele drainage was reduced to less than 10 mL per 24 hours after bleomycin sclerosis in all patients. Three patients required two sessions, and the fourth patient required three sessions. No patient developed recurrent symptoms suggesting reaccumulation of lymph during an average follow-up period of 11 months (range, 6-18 months). No complications related to percutaneous lymphocele drainage or sclerosant therapy were encountered.
  
  
  CONCLUSIONS
  Percutaneous intracavitary instillation of bleomycin may be considered as an alternative to surgery in patients who have undergone unsuccessful lymphocele sclerosis with other agents.
authors.affiliation: Department of Radiology, University of California, San Francisco, 94143-0628, USA.
authors.forename: R K
authors.initials: RK
authors.lastname: Kerlan
authors.forename: J M
authors.initials: JM
authors.lastname: LaBerge
authors.forename: R L
authors.initials: RL
authors.lastname: Gordon
authors.forename: E J
authors.initials: EJ
authors.lastname: Ring
mesh_terms: D000328:Adult; D000368:Aged; D001761:Bleomycin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004322:Drainage; D005260:Female; D005471:Fluoroscopy; D006801:Humans; D008210:Lymphocele / Q000209:etiology / Q000628:therapy*; D008297:Male; D010388:Pelvis / Q000601:surgery; D011183:Postoperative Complications; D015641:Radiography, Interventional; D012597:Sclerosing Solutions / Q000627:therapeutic use*; D015911:Sclerotherapy
chemical_list: D012597:Sclerosing Solutions; D001761:Bleomycin